类风湿关节炎患者接受(超)低剂量利妥昔单抗治疗时药物水平、抗药抗体及B细胞计数不能预测治疗反应
REDO试验的预设二次分析纳入140例类风湿关节炎(RA)患者,比较1000 mg、500 mg及200 mg利妥昔单抗再治疗后的药物水平、抗药抗体(ADAs)和B细胞计数及其与治疗反应的关系。结果显示较低剂量导致较低药物水平,但未显著影响ADAs或B细胞计数;各剂量组分别有3例(10.7%)、12例(20.7%)和7例(13.0%)未达到反应标准;药物水平、ADAs、B细胞计数及患者、疾病和治疗特征均不能预测超低剂量利妥昔单抗的治疗反应。
要点
- 在REDO试验的140例RA患者中,1000 mg、500 mg和200 mg利妥昔单抗组分别有3例(10.7%)、12例(20.7%)和7例(13.0%)未达到反应标准。
- 较低剂量利妥昔单抗导致较低药物水平,但未显著影响抗药抗体水平或B细胞计数。
- 药物水平、抗药抗体、B细胞计数以及患者、疾病和治疗特征均不能预测超低剂量利妥昔单抗的治疗反应。
核心结论
- 本研究结果进一步支持以下假说:对于利妥昔单抗治疗反应良好的RA患者,继续使用500 mg或200 mg利妥昔单抗与1000 mg剂量同样有效。
- 结合原REDO研究未发现临床剂量-反应关系,这些结果提示200 mg利妥昔单抗尚不是RA中最低的有效利妥昔单抗再治疗剂量。
研究设计与样本
- REDO试验(REtreatment with Rituximab in RhEumatoid arthritis: Disease Outcome after Dose Optimisation)的预设二次分析,纳入140例RA患者。
- 在基线以及给药后3个月和6个月时检查利妥昔单抗药物水平、抗药抗体(ADAs)和B细胞计数的差异。
- 治疗反应定义为随访期间无疾病复发且未接受额外利妥昔单抗或未接受超过1次糖皮质激素注射。
- 采用逻辑回归分析探讨潜在预测因素与治疗反应之间的关联。
主要发现
- 较低剂量利妥昔单抗导致较低药物水平,但未显著影响抗药抗体水平或B细胞计数。
- 1000 mg、500 mg和200 mg剂量组分别有3例(10.7%)、12例(20.7%)和7例(13.0%)患者未达到反应标准。
- 药物水平、抗药抗体、B细胞计数以及患者、疾病和治疗特征均不能预测超低剂量利妥昔单抗的治疗反应。
关键数值与推荐
- 治疗反应定义为随访期间无疾病复发且未接受额外利妥昔单抗或未接受超过1次糖皮质激素注射。
- 1000 mg剂量组有3例(10.7%)未达到反应标准。
- 500 mg剂量组有12例(20.7%)未达到反应标准。
- 200 mg剂量组有7例(13.0%)未达到反应标准。
临床怎么用
- 原文结论未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The REDO trial (REtreatment with Rituximab in RhEumatoid arthritis: Disease Outcome after Dose Optimisation) showed that ultra-low-dose rituximab (500 mg or 200 mg) was similarly effective to a 1000 mg dosage in the majority of RA patients. This pre-planned secondary analysis investigated (1) associations between rituximab dosage, drug levels, anti-drug antibodies (ADAs) and B-cell counts and (2) the predictive value of pharmacokinetic and pharmacodynamic parameters, and of patient, disease and treatment characteristics in relation to response to ultra-low-dose rituximab. METHODS: For 140 RA patients from the REDO trial, differences in drug levels, ADAs and B-cell counts were examined at baseline, and at 3 and 6 months after dosing. Treatment response was defined as absence of flare and no extra rituximab or >1 glucocorticoid injection received during follow-up. The association between potential predictors and response was investigated using logistic regression analyses. RESULTS: Lower doses of rituximab resulted in lower drug levels but did not significantly affect ADA levels or B-cell counts, and 3 (10.7%), 12 (20.7%) and 7 (13.0%) patients failed to meet the response criteria in, respectively, the 1000 mg, 500 mg and 200 mg dosage groups. Drug levels, ADAs, B-cell counts, and patient, disease and treatment characteristics were not predictive for response to ultra-low-dose rituximab. CONCLUSION: The results of this study further support the hypothesis that continued treatment with 500 or 200 mg rituximab is similarly effective to a 1000 mg dosage in RA patients doing well on rituximab. These results, combined with lack of finding a clinical dose-response relationship in the original REDO study, suggest that 200 mg rituximab is not yet the lowest effective rituximab retreatment dose in RA.
引用
- Wientjes MHM, Gijzen TMG, den Broeder N, et al. Drug levels, anti-drug antibodies and B-cell counts were not predictive of response in rheumatoid arthritis patients on (ultra-)low-dose rituximab. Rheumatology (Oxford). 2022. PMID: 35022672. doi:10.1093/rheumatology/keac024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。